The best hair loss treatments of 2026
Finasteride, minoxidil, and drug-free options compared on efficacy, side effects, and price. Independently reviewed against the clinical evidence.
Independent. We sell nothing we review — affiliate links never change our scores.Quick verdict: Happy Head Prescription Topical is our top pick — strongest on effectiveness (8.3/10).
Our top picks at a glance
The standout in each category, by our 6-axis scores. Tap a pick to jump to its full breakdown.
Summary of recommendations
Happy Head's prescription topical is a custom-compounded scalp solution that combines FDA-approved minoxidil (up to 8%) with topical finasteride and other actives, prescribed through a telehealth dermatologist. It can help regrow hair with lower systemic drug exposure than oral pills, but the topical-finasteride portion is compounded and not FDA-approved, side effects can still occur, and any regrowth reverses if you stop using it.
We score all 6 hair loss products we track on the same six-axis rubric and rank every one of them here — including the lower scorers. Nothing is hidden or bumped up for paying us.
Every product here is scored on the same six-criteria rubric, fact-checked against authoritative sources (FDA, PubMed, clinical guidelines), and linked inline so you can verify it. We make nothing we review, and affiliate links never change a ranking. Full methodology →
The two treatments with the strongest evidence for the most common kind of hair loss (androgenetic alopecia) are topical minoxidil and oral finasteride — both FDA-approved, both inexpensive as generics, and both requiring continuous use to keep any gains. Almost everything else on the market is either a weaker add-on, an off-label prescription with real trade-offs, or a supplement whose marketing runs far ahead of its data — so the smartest first move is matching a proven treatment to your specific type of hair loss rather than chasing the most-advertised product.
What are the hair loss treatment options and how do they work?
Hair loss is not one problem, and "treatments" only make sense once you know which type you have. The vast majority of products you'll see advertised target androgenetic alopecia (male- and female-pattern hair loss), the genetic, hormone-driven miniaturization of follicles that affects most men and roughly half of women over a lifetime (NIH/StatPearls). A smaller set of options targets autoimmune alopecia areata, and temporary shedding (telogen effluvium) usually needs no product at all — it resolves once the trigger passes.
For pattern hair loss, the credible options fall into a few mechanisms:
- Minoxidil (topical or oral). Originally a blood-pressure drug, minoxidil extends the follicle's growth (anagen) phase and appears to improve blood flow to the follicle. Topical 2% and 5% solutions and foam are the only FDA-approved over-the-counter treatment for pattern loss. Low-dose oral minoxidil (typically 0.25–2.5 mg for women, 2.5–5 mg for men) is prescribed off-label and has become widely used because adherence is easier and efficacy is at least comparable (PMID 38315101; meta-regression showing a positive dose-dependent effect, PMID 36161084).
- 5-alpha-reductase inhibitors (finasteride, dutasteride). These lower dihydrotestosterone (DHT), the androgen that drives follicle miniaturization. Oral finasteride 1 mg is FDA-approved for men; dutasteride is more potent and used off-label. Topical finasteride is marketed as a way to lower systemic exposure, but no topical finasteride product is FDA-approved in the U.S. — it is dispensed only as a compounded formulation, and in 2025 the FDA issued a safety alert warning of adverse-event reports tied to compounded topical finasteride.
- Anti-androgens (spironolactone). Used off-label in women, often alongside minoxidil, to blunt androgen effects on the follicle.
- Low-level laser/light therapy (LLLT). FDA-*cleared* (a lower bar than "approved") devices — caps, combs, helmets — that may stimulate follicles via photobiomodulation.
- Procedures. Platelet-rich plasma (PRP) injections and surgical hair transplantation, which redistributes your own DHT-resistant follicles.
- JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib). FDA-approved for *severe alopecia areata* only — not pattern hair loss.
- Supplements / nutraceuticals. Saw palmetto, biotin, marine collagen, and branded blends (e.g., Nutrafol). Mechanisms are plausible but rarely proven.
What does the evidence actually show?
This is where an honest guide diverges from product marketing. Evidence strength varies enormously by treatment.
- Topical minoxidil — strong. Multiple randomized trials and meta-analyses confirm it slows loss and partially regrows hair in men and women; the AAD and a major systematic review of androgenetic alopecia treatments both support it (PMID 28396101). It is one of only two treatments with regulatory approval for OTC use.
- Oral finasteride — strong (men). In the pivotal trials, hair counts improved versus placebo, and a systematic review found mean hair count rose roughly 9% short-term and up to ~24% long-term versus placebo (PMID 20956649; PMID 11907500). Five-year data show it reduces the likelihood of further visible loss (PMID 18573712). It is not used in women of childbearing potential because of fetal risk.
- Low-dose oral minoxidil — moderate and growing. A 2024 systematic review and a meta-regression both support efficacy, with a positive dose-dependent effect; the main caveat is that most evidence comes from observational and single-arm studies rather than large placebo-controlled trials (PMID 38315101; PMID 36161084).
- Dutasteride — moderate. Head-to-head and dose-finding studies suggest it is at least as effective as finasteride and possibly more so, but it is off-label for hair loss and has a longer half-life.
- Low-level laser therapy — moderate but mixed. Meta-analyses of FDA-cleared home devices show a statistically significant increase in hair density versus sham, but effect sizes are modest, trials are short, and many were industry-funded (PMID 34546105; PMID 30706177). Reasonable as an *add-on*, weak as a standalone.
- PRP — limited. Small trials suggest possible benefit, but protocols, preparation methods, and outcomes are inconsistent, and high-quality evidence is lacking.
- Saw palmetto — limited. The most-cited trial (Rossi 2012, an open-label 2-year study of about 100 men) found 38% of the saw palmetto group improved versus 68% on finasteride — i.e., finasteride was clearly superior, and the trial had no placebo arm. Overall the evidence remains low-quality, and reviewers consider it insufficient to recommend saw palmetto as a substitute for proven treatments.
- Branded nutraceuticals (e.g., Nutrafol) — limited and conflicted. The supporting trials are small, frequently company-funded, sometimes authored by founders, and often rely on self-reported outcomes rather than standardized hair counts — and some enrolled people with self-resolving telogen effluvium, which can confound results. A class-action complaint has even challenged "clinically proven" marketing claims. None of this proves the products *don't* help, but it means you should not treat them as equivalent to FDA-approved drugs.
- JAK inhibitors — strong, but only for severe alopecia areata. Baricitinib (2022), ritlecitinib (2023), and deuruxolitinib (2024) are FDA-approved for that autoimmune condition and produce substantial regrowth in a meaningful share of patients. They do nothing proven for pattern hair loss and carry boxed-warning–class risks.
How to choose: what to look for
1. Confirm your type of hair loss first. The single biggest mistake is buying a pattern-hair-loss product for shedding that's actually telogen effluvium (which self-corrects) or for a scarring alopecia (which is time-sensitive and needs a dermatologist). Patchy round bald spots, scalp pain, redness, scaling, or a smooth shiny scalp are red flags that warrant evaluation before you buy anything.
2. Prioritize the proven actives, at the right dose.
- Minoxidil: Look for 5% for men and 2% or 5% for women as the foam or solution. The active ingredient — not the brand — is what works; a generic 5% minoxidil and a premium-branded 5% minoxidil are pharmacologically the same.
- Finasteride: The studied oral dose is 1 mg daily. Higher doses (e.g., the 5 mg sold for prostate enlargement) offer little extra hair benefit.
- Combination products (e.g., topical minoxidil + finasteride) can improve convenience, but make sure each active is at an evidence-based concentration.
3. Check the credentials behind a telehealth or compounded offering. Many hair-loss "brands" are really telehealth front-ends that prescribe generic minoxidil/finasteride. That's fine — but verify there is a licensed prescriber involved, that compounded formulas list exact concentrations of each active, and that you can see ingredient labels before paying.
4. Match the format to your adherence. These treatments only work while you use them. A foam you'll actually apply daily beats a solution you abandon; a daily pill beats a topical you skip. Honest self-assessment of routine matters more than marginal differences in formulation.
5. Price-check the generic. Generic minoxidil and finasteride are inexpensive. A subscription that bundles them at a steep markup, or pads the formula with unproven "boosters," is paying brand tax for commodity drugs.
What to avoid: common marketing traps
- "Clinically proven" with no citation. Demand to know *which* study, *what* it measured (standardized hair counts beat before/after photos and self-reports), and *who funded it.* Founder-authored, company-funded, self-report studies are the weakest tier.
- Biotin for hair growth. Biotin only helps the rare person with a true biotin deficiency; for everyone else there's no good evidence it regrows hair, and high doses can distort lab tests (including thyroid and troponin assays).
- Proprietary blends that hide doses. If a supplement label says "proprietary blend" without per-ingredient amounts, you can't tell whether any active is at an effective dose.
- "DHT-blocking" shampoos and ketoconazole hype. Ketoconazole shampoo may be a minor adjunct, but no shampoo is a substitute for minoxidil or finasteride.
- Anything promising regrowth from a long-bald, shiny scalp. Once follicles are gone (scarring alopecia, or very advanced pattern loss), no topical or pill brings them back — that's a transplant conversation.
- Megadose vitamins. Excess vitamin A and selenium can *cause* hair loss; more is not better.
Safety, side effects & who should talk to a doctor first
No hair-loss treatment is risk-free, and several require medical oversight:
- Minoxidil (topical): scalp irritation, and an expected *temporary increase in shedding* in the first few weeks. Oral minoxidil: unwanted body/facial hair (hypertrichosis) is the most common effect; fluid retention and, rarely, cardiovascular effects mean it should be prescribed and monitored.
- Finasteride/dutasteride: a minority of men report sexual side effects (reduced libido, erectile or ejaculatory changes); most resolve on stopping, though persistent symptoms are reported by some. These drugs lower PSA, which matters for prostate cancer screening — tell your doctor. They are contraindicated in pregnancy and women who are or may become pregnant should not even handle crushed/broken tablets.
- Spironolactone: can raise potassium and affect menstrual cycles; not for use in pregnancy.
- JAK inhibitors: carry class warnings for serious infections, blood clots, and other risks; strictly specialist-managed.
Talk to a clinician before starting if you: are pregnant, breastfeeding, or could become pregnant; have heart, kidney, or blood-pressure conditions; take other medications; have sudden, patchy, painful, or scarring-type loss; or have hair loss alongside fatigue, weight change, or menstrual irregularity (possible thyroid, iron, or hormonal cause that a product won't fix).
Who is this category right for, and who should skip it?
Good fit: people with gradual, patterned thinning (a widening part, receding hairline, or crown thinning) who want to *slow loss and modestly regrow* hair and are willing to commit to ongoing use. The earlier you start, the more follicles you preserve — these drugs protect existing hair better than they revive long-dormant follicles.
Should skip (or see a doctor instead): anyone with sudden diffuse shedding after illness, childbirth, or crash dieting (likely telogen effluvium — usually self-resolving in 3–6 months); anyone with smooth bald patches, scalp pain, scaling, or pustules (needs diagnosis, possibly urgent for scarring alopecia); women who are or may become pregnant (avoid finasteride/dutasteride/spironolactone); and anyone expecting a cure — these are management tools, not one-time fixes.
How we evaluate
HealthVetted is an independent review site: we charge nothing for placement and sell no products. For this category we weight evidence quality most heavily — favoring FDA-approved actives and treatments backed by randomized, placebo-controlled trials with standardized hair-count outcomes over self-reported or company-funded data. We then assess transparency (are doses and actives disclosed?), value versus the generic equivalent, safety and required monitoring, and the credibility of any clinical or prescriber claims. See our full evaluation rubric and methodology for how scores are assigned.
Frequently asked questions
What's the single best hair loss treatment? There isn't one "best" for everyone — it depends on your type and sex. For male pattern loss, the strongest evidence supports finasteride and minoxidil (often used together). For female pattern loss, minoxidil is first-line, sometimes with off-label spironolactone or low-dose oral minoxidil. For autoimmune alopecia areata, treatment is different entirely (steroids or, for severe cases, JAK inhibitors).
Do I have to use it forever? For pattern hair loss, essentially yes. Minoxidil and finasteride maintain results only while you keep using them; stopping typically reverses gains over several months. Budget for it as ongoing maintenance, not a course.
How long until I see results? Hair grows slowly. Most treatments need 3–6 months of consistent use before visible change, and minoxidil often causes a brief *increase* in shedding early on before improvement appears.
Are expensive subscription brands better than generic minoxidil and finasteride? Usually not on the merits. The active ingredients are identical to inexpensive generics. You may pay for convenience (telehealth prescribing, delivery) or for unproven added "boosters" — which is a value judgment, not a clinical one.
Do supplements like biotin, collagen, or saw palmetto work? Biotin helps only with a genuine deficiency. Saw palmetto has limited, low-quality evidence and was clearly outperformed by finasteride in the main head-to-head trial. Branded blends rest on small, often company-funded studies. They may be reasonable add-ons for some people, but they are not substitutes for the proven, FDA-approved options.
Best Hair Loss Treatments: side-by-side
| # | Product | Active ingredient | Starting price | FDA status | Score | Actions |
|---|---|---|---|---|---|---|
| 1 | Happy Head Prescription Topical | — | $59/mo | compounded | 8.2 | See offer → |
| 2 | Hims Hair (Finasteride + Minoxidil) | Finasteride 1mg + Minoxidil 5% | $37/mo | approved | Top ·8.3 | See offer → |
| 3 | Keeps | Finasteride 1mg + Minoxidil 5% | Best ·$25/mo | approved | 8.0 | See offer → |
| 4 | Musely Hair Formula Rx | — | $49/mo | compounded | 8.0 | See offer → |
| 5 | Vegamour GRO Hair Serum | — | $64/mo | supplement | 7.8 | See offer → |
| 6 | Nutrafol Men | Saw palmetto, Ashwagandha, Marine collagen | $88/mo | supplement | 7.0 | See offer → |
Highest combined score across six axes. Clinically proven combo via telehealth
- Most effectiveHappy Head Prescription TopicalScore: 8.7/10
- Best valueKeepsScore: 9.0/10
- Safest profileVegamour GRO Hair SerumScore: 8.6/10
- Easiest accessHims Hair (Finasteride + Minoxidil)Score: 9.0/10
- Most trustedHappy Head Prescription TopicalScore: 8.3/10
Our top picks
Happy Head Prescription Topical
Custom-compounded topical hair-loss formula
Excels at effectivenessHappy Head's prescription topical is a custom-compounded scalp solution that combines FDA-approved minoxidil (up to 8%) with topical finasteride and other actives, prescribed through a telehealth dermatologist. It can help regrow hair with lower systemic drug exposure than oral pills, but the topical-finasteride portion is compounded and not FDA-approved, side effects can still occur, and any regrowth reverses if you stop using it.
- Combines the two most evidence-backed hair-loss drugs, minoxidil and finasteride, in one daily scalp solution instead of separate products
- Topical finasteride delivers DHT-blocking benefits to the scalp with maximum blood levels more than 100 times lower than the oral pill in trials, which may reduce systemic side effects
- Dermatologist-formulated and customizable: concentrations can be adjusted and actives like ketoconazole, retinoic acid, or hydrocortisone added for your situation
- Telehealth model includes a prescriber consultation, discreet shipping, a flexible subscription you can pause or cancel, and a 6-month satisfaction guarantee
- The topical finasteride component is compounded and NOT FDA-approved; the FDA issued an April 2025 alert about systemic side effects (including ED, depression, anxiety, suicidal ideation, and brain fog) from compounded topical finasteride, with most reports describing effects that persisted after stopping
- Markedly more expensive than generic minoxidil (roughly $63 to $178/month versus about $10 to $15), and compounded prescriptions usually are not covered by insurance
- Requires ongoing daily use: any regrowth typically reverses within months if you stop, and an initial shedding phase can be discouraging
- 8% minoxidil and propylene-glycol bases can cause more scalp irritation, redness, and contact dermatitis than standard formulas, without guaranteed extra benefit
Hims Hair (Finasteride + Minoxidil)
Clinically proven combo via telehealth
Excels at accessibilityHims Hair pairs prescription topical finasteride (0.3%) and minoxidil (6%) in one daily spray for men's pattern baldness, starting around $35/month through a telehealth visit. Both ingredients have strong individual evidence, but this compounded combination is not FDA-approved as a finished product, and in April 2025 the FDA warned about sexual, mood, and cognitive side effects reported with compounded topical finasteride.
- Combines the two most evidence-backed male-pattern-baldness ingredients (finasteride + minoxidil) in a single daily step
- Convenient, fully online telehealth process with evaluation, prescription, and home delivery
- Affordable relative to many clinic treatments, starting around $35/month with no in-person visit
- Topical delivery may reduce systemic exposure versus oral finasteride for men wary of a daily pill
- The compounded topical finasteride/minoxidil combination is not FDA-approved as a finished product, and this exact formula lacks large dedicated clinical trials
- In April 2025 the FDA warned about sexual and neuropsychiatric side effects (erectile dysfunction, low libido, depression, anxiety, brain fog, insomnia) reported with compounded topical finasteride, some persisting after stopping
- It is an ongoing commitment: hair gained is typically lost within months of stopping
- Not for women, and dangerous to handle during pregnancy due to male-fetus birth-defect risk
Why it ranks lower weakest on safety.
Keeps
Lowest-cost finasteride + minoxidil subscription
Excels at valueKeeps is a legitimate US telehealth subscription that connects men to FDA-approved generic finasteride and minoxidil, the two best-evidenced hair-loss treatments, at low prices (often $10-25/month per drug). It is convenient and clinically sound, but it sells generic medications, requires indefinite use, and carries finasteride's sexual and mood side-effect risk. Note that Keeps' parent company agreed to be acquired in late 2025, so confirm current pricing and policies directly on its site.
- Prescribes the two treatments with the strongest clinical evidence for male pattern baldness: finasteride and minoxidil
- Low entry pricing (often $10-25/month per medication) with discreet home delivery and online doctor access, no in-person visit needed
- Multiple formats and combinations available, including oral finasteride, 5% topical minoxidil foam/solution, a compounded once-daily finasteride+minoxidil gel, and ketoconazole 2% shampoo
- Works best when started early on hereditary thinning, where evidence shows it can both slow loss and regrow some hair
- Finasteride carries a real (though uncommon, ~1-2%) risk of sexual side effects, plus debated reports of persistent symptoms and mood effects; depression and suicidal ideation are listed on the finasteride label as postmarketing reactions
- Results are slow (typically 3-12 months) and require lifelong use; any gains reverse within months of stopping
- You're paying largely for convenience; the underlying generics can often be bought cheaper via a GoodRx coupon at a local pharmacy
- Only for men; finasteride is contraindicated and hazardous to handle for women who are or may be pregnant
Why it ranks lower weakest on safety.
More options we considered
Musely Hair Formula Rx
Prescription topical and oral hair-growth plan
Excels at accessibilityMusely Hair Formula Rx is a prescription, pharmacy-compounded hair-loss treatment. Its topical Hair Solution typically combines high-strength minoxidil with topical dutasteride (a DHT blocker), tretinoin, spironolactone, ketoconazole, and hydrocortisone, and an oral Hair Pill pairs low-dose minoxidil with dutasteride. The multi-ingredient, combination approach is grounded in evidence, but the formulas are compounded rather than FDA-approved, and the FDA's 2025 alert about systemic side effects from compounded topical 5-alpha-reductase inhibitors (it specifically cited finasteride) applies to this drug class.
- Combines several evidence-based actives (minoxidil, dutasteride, spironolactone, tretinoin, ketoconazole) in one customized prescription, and minoxidil-plus-DHT-blocker combination therapy outperforms minoxidil alone in a 2025 meta-analysis
- Telehealth model is convenient: a short online visit with photos, prescriber review, and freshly compounded medication shipped to you
- Customizable strengths and formula variations (Classic versus Modern, men's versus women's, with or without certain actives) let a clinician tailor treatment to your case and tolerance
- Higher-strength minoxidil (8%) and a more potent DHT blocker (dutasteride) than typical over-the-counter or finasteride-based options, for those who want a stronger regimen
- Compounded formulas are not FDA-approved and are not tested for safety, potency, or efficacy the way mass-manufactured drugs are
- Musely's topical uses dutasteride, a 5-alpha-reductase inhibitor in the same class as finasteride, which the FDA flagged in a 2025 alert for systemic side effects (sexual and mood effects that sometimes persisted after stopping); dutasteride is more potent and longer-acting, so the same systemic risk reasonably applies and is not well studied as a topical
- The specific Musely product has no published clinical trial of its own; efficacy is inferred from its ingredients, and one small 2025 RCT found no short-term benefit from adding a topical DHT-blocker to minoxidil
- Not safe in pregnancy or breastfeeding and unsuitable for scarring or autoimmune hair loss, so it is not for everyone
Why it ranks lower weakest on safety.
Vegamour GRO Hair Serum
Plant-based topical for fuller-looking hair
Excels at accessibilityVegamour GRO Hair Serum is a plant-based cosmetic scalp serum, not an FDA-approved drug. The company's own 120-day study of 40 people claims up to 90% less shedding and a 56% increase in the appearance of density, but no independent peer-reviewed human trials confirm it regrows hair. It is best viewed as a cosmetic boost for early, mild thinning; FDA-approved minoxidil (and oral finasteride for men) remain the proven options for pattern hair loss.
- Vegan, drug-free, and hormone-free, with no minoxidil-style side effects such as an initial shedding phase or unwanted facial hair
- Easy, non-greasy once-daily leave-in application that layers well into normal hair routines
- Ingredient actives (red clover isoflavones, caffeine, peptides) have plausible, lab-supported mechanisms for supporting the hair growth phase
- Many users report visibly less shedding and fuller-looking hair within about three months, making it a reasonable cosmetic option for early or postpartum thinning
- Not FDA-approved for hair loss and not designed to regrow hair in bald areas; claims are cosmetic ('appearance of density'), not drug-level regrowth
- Headline efficacy stats (up to 90% less shedding, 56% more density appearance) are best-case figures from a small, company-funded 120-day study of just 40 people, with no independent peer-reviewed human trial of the actual formula
- Expensive to maintain: roughly $39-$64 per month indefinitely, not insurance-covered, and far pricier long-term than generic minoxidil (about $10-$15/month)
- Requires patience and strict daily consistency for 3-4 months, and any benefit stops once you quit
Why it ranks lower weakest on effectiveness.
Nutrafol Men
Physician-formulated drug-free supplement
Excels at safetyNutrafol Men is a daily botanical supplement (saw palmetto, ashwagandha, curcumin, vitamins) for men with thinning hair. A 2025 manufacturer-funded RCT found blinded investigators rated hair growth "improved" in 79% of users versus 51% on placebo at 6 months. It's drug-free and generally well-tolerated, but the evidence is modest and largely subjective, and it's weaker and pricier than finasteride or minoxidil.
- Backed by an actual peer-reviewed, randomized, double-blind, placebo-controlled trial—rare for a hair supplement—showing statistically significant improvement over placebo at 6 months
- Drug-free and generally well tolerated, with only mild, mostly gastrointestinal side effects and no serious adverse events reported in the trial
- Available over the counter without a prescription, and frequently recommended by dermatologists as an adjunct for early thinning
- Targets multiple contributors to thinning (DHT, stress, oxidative stress, micronutrients) rather than a single mechanism, and can be combined with proven treatments like finasteride or minoxidil
- The trial's objective primary endpoint (terminal hair count) was abandoned due to unusable data, so the headline benefits rest on subjective investigator ratings and self-report questionnaires rather than measured hair counts
- Manufacturer-funded study (Nutraceutical Wellness Inc.) with several authors employed by or paid as advisors to the company, a clear conflict of interest; an independent critique also notes earlier Nutrafol trials were run mainly in women
- Expensive—roughly $79-$88/month with no insurance coverage—versus generic finasteride/minoxidil that cost a fraction and have far stronger regrowth evidence
- Requires four capsules daily and at least 3-6 months of consistent use, and benefits likely fade after stopping
Why it ranks lower weakest on value.
Frequently asked questions
What is the most effective hair loss treatment?
For androgenetic alopecia (pattern hair loss), the two treatments with the strongest evidence and FDA approval are topical minoxidil and oral finasteride (men only). They work best together. Finasteride slows progression and produces visible regrowth in up to about two-thirds of men with mild-to-moderate loss, and a 10-year follow-up study found roughly 86% of men benefited (only about 14% had further visible loss), with efficacy holding up over time for most.
Minoxidil prolongs the growth phase and is the only topical proven for both men and women. No single product works for everyone, and "most effective" depends on your sex, the cause of your loss, and how early you start. A board-certified dermatologist can confirm your diagnosis and combine treatments for the best result.
What are the only FDA-approved hair loss treatments?
As of 2026, the medications FDA-approved specifically for androgenetic alopecia are:
- Topical minoxidil (2% solution or 5% solution/foam) for men and women.
- Oral finasteride 1 mg (Propecia and generics) for men only.
Separately, dozens of low-level laser therapy (LLLT) devices (more than 30 home-use devices as of recent reviews) have FDA 510(k) clearance as safe for pattern hair loss; clearance is a lower bar than drug approval but still requires a safety review.
Important: topical finasteride is not FDA-approved, and in April 2025 the FDA warned about systemic side effects from compounded topical finasteride. Oral minoxidil and spironolactone are used off-label (not FDA-approved for hair loss) but are commonly prescribed by dermatologists. For severe alopecia areata (a different, autoimmune condition), the FDA has approved oral JAK inhibitors, but those are not treatments for pattern hair loss.
Do minoxidil and finasteride have side effects?
Both are generally well tolerated, but they have distinct risks.
Minoxidil (topical): Common effects include scalp itching, dryness, and irritation. Some users grow fine unwanted facial or hand hair, and an initial shedding phase in the first 2-8 weeks is normal before regrowth. Effects reverse within months (typically about 3-6) if you stop.
Finasteride (oral): In the pivotal 1-year clinical trials, sexual side effects were uncommon, with decreased libido around 1.9% and erectile dysfunction around 1.4% in the finasteride group (versus 1.3% and 0.9% on placebo); most resolved after stopping. A subset of users report persistent symptoms, so counseling matters. Finasteride is teratogenic (former pregnancy category X) and must not be used or handled by anyone who is or may become pregnant. It also lowers PSA, which affects prostate cancer screening.
Discuss your full health history with a clinician before starting either.
Can women use the same hair loss treatments as men?
Partly. Topical minoxidil is FDA-approved for women and is the standard first-line treatment for female pattern hair loss; the 5% formulation is generally more effective than 2%.
Finasteride is not approved for women and is generally avoided in those who could become pregnant because of serious birth-defect risk. For women, dermatologists often add off-label options such as spironolactone (an anti-androgen) or low-dose oral minoxidil, depending on the case.
Women with new or unexplained thinning should see a dermatologist, because hair loss in women can signal other conditions (thyroid issues, iron deficiency, hormonal changes) that need separate evaluation and treatment.
How long until hair loss treatments show results?
Patience is essential. Hair grows slowly, so you typically need at least 3-6 months of consistent use to judge whether a treatment is working, with peak results often around 12 months (and sometimes up to 18). With minoxidil, an early shedding phase in the first couple of months is expected and usually reverses.
These treatments are also maintenance therapy, not cures. Benefits of minoxidil and finasteride reverse within months of stopping, so results depend on ongoing use. If you see no change after a full year of correct, consistent use, ask your dermatologist about adjusting the plan.
Do laser caps, PRP, and supplements actually work for hair loss?
Low-level laser therapy (LLLT): FDA-cleared laser caps and combs have randomized controlled trial support; sham-controlled studies showed statistically significant increases in hair density. Results are modest, and devices generally work best as an adjunct to medication.
Platelet-rich plasma (PRP): This in-office injection of your own concentrated platelets shows promising results for pattern hair loss in studies, typically requiring several sessions. Evidence is encouraging but less standardized than for FDA-approved drugs, and PRP is not FDA-approved for hair loss.
Supplements and shampoos: Most lack high-quality evidence. Biotin only helps in a genuine (rare) deficiency, and most "DHT-blocking" shampoos aren't proven. Correcting a documented deficiency (such as iron) can help, but supplements aren't a substitute for proven treatments.
When should I see a dermatologist about hair loss?
See a board-certified dermatologist if you notice:
- Sudden, rapid, or patchy hair loss.
- Bald patches, redness, scaling, pain, or itching of the scalp (possible scarring alopecia or other conditions).
- Hair loss as a woman, or at a young age, where causes are more varied.
- No improvement after a full year of correct over-the-counter treatment.
Getting the right diagnosis matters because pattern hair loss, alopecia areata, telogen effluvium, and scarring alopecias are treated very differently. A dermatologist can also safely manage prescription and off-label options, monitor side effects, and help you avoid unregulated compounded products. This information is educational and not a substitute for evaluation by a qualified clinician.
Sources behind the products ranked above
- Propecia (finasteride) Tablets — FDA Prescribing Information / Label — U.S. Food and Drug Administration (FDA) (2022)
- Propecia — finasteride tablet, film coated (DailyMed Label) — DailyMed, U.S. National Library of Medicine (NIH) (2022)
- Minoxidil Topical Solution, 5% — minoxidil solution (DailyMed Label) — DailyMed, U.S. National Library of Medicine (NIH) (2023)
- Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial — Journal of the European Academy of Dermatology and Venereology (JEADV) (2022)
- A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia — International Journal of Dermatology (2018)
- Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials — Frontiers in Medicine (2025)
- Randomized controlled trial on the efficacy and safety of the combination therapy of topical 0.1% finasteride - 5% minoxidil in male androgenetic alopecia — Archives of Dermatological Research (2025)
- Comparative Efficacy of Topical Finasteride (0.25%) in Combination with Minoxidil (5%) Against 5% Minoxidil or 0.25% Finasteride Alone in Male Androgenetic Alopecia: A Pilot, Randomized Open-Label Study — International Journal of Trichology (2023)
- An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia — Dermatology (2004)
- Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study — Journal of the American Academy of Dermatology (JAAD) (2016)
- The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis — Clinical Interventions in Aging (2019)
- There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses — Skin Appendage Disorders (2022)
- Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring — JAAD International (2023)
- Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review — Journal of Clinical Medicine (2025)
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations — Frontiers in Pharmacology (2025)
- Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis — Acta Dermato-Venereologica (2018)
- The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis — Cureus (2023)
- The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis — Frontiers in Medicine (2023)
- Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review — Dermatologic Therapy (2020)
- Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes — Journal of Dermatological Treatment (2020)
- Interventions for female pattern hair loss (Cochrane Systematic Review) — Cochrane Database of Systematic Reviews (2016)
- Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia (NCT07273799) — ClinicalTrials.gov, U.S. National Library of Medicine (NIH) (2025)
- Hair Loss Treatment Science & Research (Manufacturer Clinical Evidence Page) — Happy Head (manufacturer) (2026)
- Finasteride Tablet, Film Coated — Prescribing Information (DailyMed Label) — DailyMed, U.S. National Library of Medicine (NIH) (2023)
- Propecia (finasteride) 1 mg — Approval Package / Medical Review — U.S. Food and Drug Administration (FDA) (2011)
- Minoxidil Topical Solution 5% — minoxidil solution (DailyMed Label) — DailyMed, U.S. National Library of Medicine (NIH) (2023)
- Minoxidil Topical Solution 2% — solution (DailyMed Label) — DailyMed, U.S. National Library of Medicine (NIH) (2023)
- Minoxidil — StatPearls (Mechanism of Action, Efficacy, Safety) — StatPearls, NCBI Bookshelf (NIH) (2024)
- Androgenetic Alopecia — StatPearls (Pathogenesis, Epidemiology, Treatment) — StatPearls, NCBI Bookshelf (NIH) (2024)
- Male Androgenetic Alopecia — Endotext — Endotext, NCBI Bookshelf (NIH) (2019)
- Long-term (5-year) Multinational Experience with Finasteride 1 mg in the Treatment of Men with Androgenetic Alopecia — European Journal of Dermatology (PubMed) (2002)
- Long-term Treatment with Finasteride 1 mg Decreases the Likelihood of Developing Further Visible Hair Loss in Men with Androgenetic Alopecia — European Journal of Dermatology (PubMed) (2008)
- Finasteride, 1 mg Daily Administration on Male Androgenetic Alopecia in Different Age Groups: 10-Year Follow-up — Dermatologic Therapy (PubMed) (2011)
- Safety of Low-dose Oral Minoxidil Treatment for Hair Loss: A Systematic Review and Pooled-analysis of Individual Patient Data — Journal of the American Academy of Dermatology (PubMed) (2021)
- There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: A Systematic Review with Meta-Regression Analyses — Skin Appendage Disorders (PubMed Central, NIH) (2022)
- The Effectiveness of Combination Therapies for Androgenetic Alopecia: A Systematic Review and Meta-analysis — Journal of the American Academy of Dermatology (PubMed) (2020)
- Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service Evaluation — Skin Health and Disease (PubMed Central, NIH) (2024)
- Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis — JAMA Dermatology (PubMed Central, NIH) (2022)
- The Efficacy and Safety of 5α-Reductase Inhibitors in Androgenetic Alopecia: A Network Meta-analysis and Benefit-Risk Assessment of Finasteride and Dutasteride — Journal of the American Academy of Dermatology (PubMed) (2013)
- Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs — Clinical, Cosmetic and Investigational Dermatology (PubMed Central, NIH) (2023)
- Ketoconazole Shampoo: Effect of Long-term Use in Androgenic Alopecia — Dermatology (PubMed) (1998)
- Ketoconazole as an Adjunct to Finasteride in the Treatment of Androgenetic Alopecia in Men — Medical Hypotheses (PubMed) (2004)
- Persistent Sexual Side Effects of Finasteride for Male Pattern Hair Loss — Journal of Sexual Medicine (PubMed) (2011)
- Epidemiological Landscape of Androgenetic Alopecia in the US: An All of Us Cross-sectional Study — PLOS One (PubMed Central, NIH) (2025)
- Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia (NCT04293822) — ClinicalTrials.gov, U.S. National Library of Medicine (NIH) (2020)
- Topical Finasteride & Minoxidil Men's Rx Hair Loss Spray — Product & Clinical Information — Hims (Hims & Hers Health, Inc.) — Manufacturer (2025)
- Propecia (finasteride) tablet, film coated — FDA Prescribing Information — DailyMed, U.S. National Library of Medicine (NIH) (2021)
- Propecia (finasteride) Tablets, 1 mg — Highlights of Prescribing Information — U.S. Food and Drug Administration (FDA) (2021)
- Finasteride in the treatment of men with androgenetic alopecia — Journal of the American Academy of Dermatology (Kaufman KD, et al.) (1998)
- A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men — Journal of the American Academy of Dermatology (2002)
- A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men — Journal of the American Academy of Dermatology (2007)
- Effectiveness and safety of 5% minoxidil foam in the treatment of male pattern hair loss (NCT00151515) — ClinicalTrials.gov, U.S. National Library of Medicine (2008)
- Single and repeated dose of finasteride topical solution in subjects with androgenetic alopecia: a pharmacokinetic and pharmacodynamic study — Journal of the American Academy of Dermatology (2013)
- Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial — JAMA Dermatology (2024)
- Persistent Sexual, Emotional, and Cognitive Impairment Post-Finasteride: A Survey of Men Reporting Symptoms — American Journal of Men's Health (2015)
- Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review — Frontiers in Pharmacology (2025)
- Study to Evaluate the Efficacy and Safety of P-3074 (Topical Finasteride) Solution in the Treatment of Androgenetic Alopecia (NCT03004469) — ClinicalTrials.gov, U.S. National Library of Medicine (2017)
- Minoxidil: a comprehensive review — Journal of Dermatological Treatment (2021)
- Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review — Acta Dermato-Venereologica (2010)
- Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials — Frontiers in Medicine (2025)
- Topical tretinoin for hair growth promotion — Journal of the American Academy of Dermatology (1986)
- The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review — Clinical, Cosmetic and Investigational Dermatology (2023)
- A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia — Journal of the American Academy of Dermatology (2012)
- Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata — Journal of the American Academy of Dermatology (2009)
- Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version — Journal of the European Academy of Dermatology and Venereology (JEADV) (2018)
- Understanding the Risks of Compounded Drugs — U.S. Food and Drug Administration (FDA) (2023)
- Human Drug Compounding — U.S. Food and Drug Administration (FDA) (2024)
- GRO Hair Serum (official product page, ingredients & 120-day clinical claims) — Vegamour (manufacturer) (2024)
- Vegamour GRO Hair Serum — full INCI ingredient list — INCIDecoder (2024)
- An Herbal Extract Combination (Biochanin A, Acetyl tetrapeptide-3, and Ginseng Extracts) versus 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A 24-week, Prospective, Randomized, Triple-blind, Controlled Trial — The Journal of Clinical and Aesthetic Dermatology (2020)
- Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study — Journal of Dermatological Treatment (2012)
- Preparation and evaluation of hair growth promoting effect of transferosomes containing red clover extract and caffeine alone or in combination — Avicenna Journal of Phytomedicine (2024)
- Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro — International Journal of Dermatology (2007)
- Differential effects of caffeine on hair shaft elongation, matrix and outer root sheath keratinocyte proliferation, and TGF-β2/IGF-1-mediated regulation of the hair cycle in male and female human hair follicles in vitro — British Journal of Dermatology (2014)
- Inhibitory effects of mung bean (Vigna radiata L.) seed and sprout extracts on melanogenesis — Food Science and Biotechnology (2016)
- Effect of Red Clover Isoflavones over Skin, Appendages, and Mucosal Status in Postmenopausal Women — Obstetrics and Gynecology International (2011)
- Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials — Nutrients (2021)
- Safety assessment of a highly bioavailable curcumin-galactomannoside complex (CurQfen) in healthy volunteers, with special reference to recent hepatotoxic reports of curcumin supplements: A 90-day prospective study — Toxicology Reports (2021)
- An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia — Skin Pharmacology and Physiology (2017)
- Cyclodextrin-Assisted Extraction Method as a Green Alternative to Increase the Isoflavone Yield from Trifolium pratense L. Extract — Molecules (2021)
- Curcumin, an active component of turmeric: biological activities, nutritional aspects, immunological, bioavailability, and human health benefits — a comprehensive review — Frontiers in Immunology (2025)
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair — Journal of Cosmetic Dermatology (PubMed, Bhatia N, Ablon G, Farris PK, et al.) (2025)
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair (full text) — Journal of Cosmetic Dermatology (Wiley Online Library) (2025)
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair (PMC full text) — Journal of Cosmetic Dermatology (PubMed Central) (2025)
- A Six-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Women With Self-Perceived Thinning Hair — Journal of Drugs in Dermatology (PubMed, Ablon G, et al.) (2018)
- A Prospective Six-month Single-blind Study Evaluating Changes in Hair Growth and Quality Using a Nutraceutical Supplement in Men and Women of Diverse Ethnicities — Journal of Clinical and Aesthetic Dermatology (PubMed) (2022)
- Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia — Skin Appendage Disorders (Karger) (2020)
- Oral and Topical Administration of a Standardized Saw Palmetto Oil Reduces Hair Fall and Improves the Hair Growth in Androgenetic Alopecia Subjects - A 16-Week Randomized, Placebo-Controlled Study — Journal of Cosmetic Dermatology (PubMed) (2024)
- An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study — Medicine (Baltimore) (PubMed Central, Lopresti AL, et al.) (2019)
- Effects of Ashwagandha (Withania somnifera) on stress and anxiety: A systematic review and meta-analysis — Explore (Journal of Science and Healing, ScienceDirect) (2024)
- Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials — International Journal of Molecular Sciences (PubMed Central) (2023)
- Effects of Tocotrienol Supplementation on Hair Growth in Human Volunteers — Tropical Life Sciences Research (PubMed, Beoy LA, Woei WJ, Hay YK) (2010)
- Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair loss (AGA, FAGA or telogen effluvium): A prospective, randomized, 3-month, controlled, assessor-blinded study — Skin Research and Technology (PubMed Central, Milani M, et al.) (2023)
- Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis — Frontiers in Nutrition (Zhou L, Zhu W, Chen Y) (2026)
- The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis — Journal of the American Academy of Dermatology (PubMed, Gupta AK, et al.) (2017)
- Medical and procedural treatment of androgenetic alopecia - Where are we? — Journal of the American Academy of Dermatology (2023)
- Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials — Frontiers in Medicine (2025)
- Dietary Supplements — U.S. Food and Drug Administration (FDA) (2024)
- Structure/Function Claims — U.S. Food and Drug Administration (FDA) (2024)
- Questions and Answers on Dietary Supplements — U.S. Food and Drug Administration (FDA) (2024)
- Nutrafol Men is Clinically Proven to Improve Hair Growth (clinical study summary) — Nutrafol (manufacturer clinical page) (2025)